Precipitated Opioid Withdrawal After Buprenorphine Administration in Patients Presenting to the Emergency Department: A Case Series

Overview

Journal J Am Coll Emerg Physicians Open

Publisher Elsevier

Specialty Emergency Medicine

Date 2023 Jan 27

PMID 36704210

Authors

Anthony Spadaro

Sophia Faude

Jeanmarie Perrone

Ashish P Thakrar

Margaret Lowenstein

M Kit Delgado

Austin S Kilaru

Affiliations

Soon will be listed here.

Abstract

Objectives: Buprenorphine is a highly effective medication for the treatment of opioid use disorder, but it can cause precipitated withdrawal (PW) from opioids. Incidence, risk factors, and best approaches to management of PW are not well understood. Our objective was to describe adverse outcomes after buprenorphine administration among emergency department (ED) patients and assess whether they met the criteria for PW.

Methods: This study is a case series using retrospective chart review in a convenience sample of patients from 3 hospitals in an urban academic health system. This study included patients who were reported by clinicians as potential cases of PW. Relevant clinical data were abstracted from the electronic health record using a structured retrospective chart review instrument.

Results: A total of 13 cases were included and classified into the following 3 categories: (1) PW after buprenorphine administration consistent with guidelines (n = 5), (2) PW after deviating from guidelines (n = 4), and (3) protracted opioid withdrawal with no increase in Clinical Opiate Withdrawal Scale score (n = 4). A total of 11 patients had urine drug testing positive for fentanyl, and 11 patients received additional doses of buprenorphine for symptom management. Of the patients, 5 had self-directed hospital discharges, and 6 were ultimately discharged with prescriptions for buprenorphine.

Conclusions: Cases of adverse outcomes after buprenorphine administration in the ED and hospital meet criteria for PW, although some cases may have represented protracted opioid withdrawal. Further investigation into the incidence, risk factors, management of PW as well as patient perspectives is needed to expand and sustain the use of buprenorphine in EDs and hospitals.

Citing Articles

Fentanyl, Heroin, Methamphetamine, and Cocaine Analyte Concentrations in Urine Drug Testing Specimens.

Huhn A, Whitley P, Bolin B, Dunn K JAMA Netw Open. 2024; 7(10):e2441063.

PMID: 39446323 PMC: 11577146. DOI: 10.1001/jamanetworkopen.2024.41063.

Buprenorphine-Precipitated Withdrawal Among Hospitalized Patients Using Fentanyl.

Thakrar A, Christine P, Siaw-Asamoah A, Spadaro A, Faude S, Snider C JAMA Netw Open. 2024; 7(9):e2435895.

PMID: 39331392 PMC: 11437388. DOI: 10.1001/jamanetworkopen.2024.35895.

Methadone Initiation in the Emergency Department for Opioid Use Disorder.

Wolfson D, King R, Lamberson M, Lyttleton J, Waters C, Schneider S West J Emerg Med. 2024; 25(5):668-674.

PMID: 39319796 PMC: 11418868. DOI: 10.5811/westjem.18530.

Effects of xylazine on naloxone-precipitated fentanyl withdrawal in male and female rats.

Carlson H, Spera A, Smith M Drug Alcohol Depend. 2024; 264:112450.

PMID: 39299010 PMC: 11527582. DOI: 10.1016/j.drugalcdep.2024.112450.

Buprenorphine Prescribing Characteristics Following Relaxation of X-Waiver Training Requirements.

Christine P, Chahine R, Kimmel S, Mack N, Douglas C, Stopka T JAMA Netw Open. 2024; 7(8):e2425999.

PMID: 39102264 PMC: 11301557. DOI: 10.1001/jamanetworkopen.2024.25999.

References

Cisewski D, Santos C, Koyfman A, Long B . Approach to buprenorphine use for opioid withdrawal treatment in the emergency setting. Am J Emerg Med. 2018; 37(1):143-150. DOI: 10.1016/j.ajem.2018.10.013. View

Strain E, Preston K, Liebson I, Bigelow G . Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone. J Pharmacol Exp Ther. 1995; 272(2):628-38. View

Lowenstein M, Kilaru A, Perrone J, Hemmons J, Abdel-Rahman D, Meisel Z . Barriers and facilitators for emergency department initiation of buprenorphine: A physician survey. Am J Emerg Med. 2019; 37(9):1787-1790. PMC: 7556325. DOI: 10.1016/j.ajem.2019.02.025. View

Kariisa M, Patel P, Smith H, Bitting J . Notes from the Field: Xylazine Detection and Involvement in Drug Overdose Deaths - United States, 2019. MMWR Morb Mortal Wkly Rep. 2021; 70(37):1300-1302. PMC: 8445380. DOI: 10.15585/mmwr.mm7037a4. View

Kempen J . Appropriate use and reporting of uncontrolled case series in the medical literature. Am J Ophthalmol. 2010; 151(1):7-10.e1. PMC: 3052978. DOI: 10.1016/j.ajo.2010.08.047. View

Silverstein S, Daniulaityte R, Martins S, Miller S, Carlson R . "Everything is not right anymore": Buprenorphine experiences in an era of illicit fentanyl. Int J Drug Policy. 2019; 74:76-83. PMC: 6914257. DOI: 10.1016/j.drugpo.2019.09.003. View

Gregory K, Radovinsky L . Research strategies that result in optimal data collection from the patient medical record. Appl Nurs Res. 2010; 25(2):108-16. PMC: 3030926. DOI: 10.1016/j.apnr.2010.02.004. View

Cunningham C, Roose R, Starrels J, Giovanniello A, Sohler N . Prior buprenorphine experience is associated with office-based buprenorphine treatment outcomes. J Addict Med. 2013; 7(4):287-93. PMC: 3737355. DOI: 10.1097/ADM.0b013e31829727b2. View

Spadaro A, Sarker A, Hogg-Bremer W, Love J, ODonnell N, Nelson L . Reddit discussions about buprenorphine associated precipitated withdrawal in the era of fentanyl. Clin Toxicol (Phila). 2022; 60(6):694-701. PMC: 10457147. DOI: 10.1080/15563650.2022.2032730. View

10.

Eaton E, Westfall A, McClesky B, Paddock C, Lane P, Cropsey K . In-Hospital Illicit Drug Use and Patient-Directed Discharge: Barriers to Care for Patients With Injection-Related Infections. Open Forum Infect Dis. 2020; 7(3):ofaa074. PMC: 7096133. DOI: 10.1093/ofid/ofaa074. View

11.

Whitley S, Sohler N, Kunins H, Giovanniello A, Li X, Sacajiu G . Factors associated with complicated buprenorphine inductions. J Subst Abuse Treat. 2010; 39(1):51-7. PMC: 4755478. DOI: 10.1016/j.jsat.2010.04.001. View

12.

Herring A, Vosooghi A, Luftig J, Anderson E, Zhao X, Dziura J . High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder. JAMA Netw Open. 2021; 4(7):e2117128. PMC: 8283555. DOI: 10.1001/jamanetworkopen.2021.17128. View

13.

Spadaro A, Long B, Koyfman A, Perrone J . Buprenorphine precipitated opioid withdrawal: Prevention and management in the ED setting. Am J Emerg Med. 2022; 58:22-26. DOI: 10.1016/j.ajem.2022.05.013. View

14.

Walley A, Alperen J, Cheng D, Botticelli M, Castro-Donlan C, Samet J . Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. J Gen Intern Med. 2008; 23(9):1393-8. PMC: 2518016. DOI: 10.1007/s11606-008-0686-x. View

15.

Moe J, Doyle-Waters M, OSullivan F, Hohl C, Azar P . Effectiveness of micro-induction approaches to buprenorphine initiation: A systematic review protocol. Addict Behav. 2020; 111:106551. DOI: 10.1016/j.addbeh.2020.106551. View

16.

DOnofrio G, OConnor P, Pantalon M, Chawarski M, Busch S, Owens P . Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015; 313(16):1636-44. PMC: 4527523. DOI: 10.1001/jama.2015.3474. View

17.

Kaji A, Schriger D, Green S . Looking through the retrospectoscope: reducing bias in emergency medicine chart review studies. Ann Emerg Med. 2014; 64(3):292-8. DOI: 10.1016/j.annemergmed.2014.03.025. View

18.

Guo C, DOnofrio G, Fiellin D, Edelman E, Hawk K, Herring A . Emergency department-initiated buprenorphine protocols: A national evaluation. J Am Coll Emerg Physicians Open. 2021; 2(6):e12606. PMC: 8630357. DOI: 10.1002/emp2.12606. View

19.

Klaire S, Zivanovic R, Barbic S, Sandhu R, Mathew N, Azar P . Rapid micro-induction of buprenorphine/naloxone for opioid use disorder in an inpatient setting: A case series. Am J Addict. 2019; 28(4):262-265. DOI: 10.1111/ajad.12869. View

20.

Sordo L, Barrio G, Bravo M, Indave B, Degenhardt L, Wiessing L . Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017; 357:j1550. PMC: 5421454. DOI: 10.1136/bmj.j1550. View